🔎 Trials Near Me

Utama › Sistem Imun dan Gangguan › California

Kajian klinikal Sistem Imun dan Gangguan di California

18 kajian untuk Sistem Imun dan Gangguan sedang mencari peserta di lokasi di California.

Bandar di California

Teks kajian rasmi (Bahasa Inggeris)

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

  • City of Hope, Duarte
  • University of California, Irvine Medical Center - Hematology/Oncology, Orange
  • Stanford University School of Medicine, Stanford
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07192471

A Study of JADE101 in Participants With Immunoglobulin A Nephropathy

  • Jade Clinical Site, Chula Vista
Mengambil pesertaFasa 2
Umur 18 hingga 60 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07541287

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  • USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles
  • University of California San Diego Center for Bleeding and Clotting Disorders, San Diego
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06722235

Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects

  • PCR Oncology, Arroyo Grande
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank
  • Washington Health, Fremont
  • dan 3 lagi
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 17 Sep 2026 · NCT04242095

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  • City of Hope Comprehensive Cancer Center, Duarte
  • UCLA Medical Center, Los Angeles
  • Stanford Cancer Institute, Stanford
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT04996875

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  • USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles
  • University of California San Diego Center for Bleeding and Clotting Disorders, San Diego
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06948318

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

  • Northridge Clinical Trials, Northridge
Mengambil pesertaFasa 3
Umur 12 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07765888

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

  • City of Hope, Duarte
  • Stanford University, Palo Alto
  • UCSF, San Francisco
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT07075185

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • University of California-Irvine Medical Center, Irvine
  • Cedars-Sinai Medical Center, Los Angeles
  • University of California, Los Angeles (UCLA) Medical Center, Los Angeles
  • dan 1 lagi
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT05826535

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

  • Inmagene Site 1, Lancaster
  • Inmagene Site 23, Los Angeles
Mengambil pesertaFasa 2
Umur 18 hingga 74 · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT07037901

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • UCLA Department of Medicine, Los Angeles
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jul 2026 · NCT07216443

Atacicept in Multiple Glomerular Diseases

  • Vera Therapeutics, Brisbane
Mengambil pesertaFasa 2
Umur 2 ke atas · Semua jantina · Dikemas kini 26 Jun 2026 · NCT06983028

A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition

  • University of California, San Francisco, San Francisco
Mengambil pesertaFasa 2
Semua umur · Semua jantina · Dikemas kini 2 Jun 2026 · NCT05787574

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

  • Stanford University, Dept. of Dermatology, Redwood City
  • UC Davis, Dept. of Dermatology, Sacramento
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Mei 2026 · NCT04422912

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • City of Hope, Duarte
  • Providence St. John's Health Center, Santa Monica
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Apr 2026 · NCT03328078

Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

  • USC / Norris Comprehensive Cancer Center, Los Angeles
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 ke atas · Semua jantina · Dikemas kini 2 Apr 2026 · NCT03207854

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

  • City of Hope National Medical Center, Duarte
  • Ronald Regan UCLA Medical Center, Los Angeles
  • University of California Irvine Health, Orange
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Dis 2025 · NCT06619561

Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions

  • Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites, Culver City
Mengambil pesertaFasa 1/2Sukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Apr 2022 · NCT04684602

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.